High Tower Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

High Tower Advisors, LLC

$64.2 Billion
Q2 2024

A detailed history of High Tower Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, High Tower Advisors, LLC holds 53,094 shares of VRTX stock, worth $26.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

53,094

Previous 57,286 7.32%

Holding current value

$26.7 Million

Previous $23.9 Million 3.93%

% of portfolio

0.04%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $1.65 Million - $2.04 Million	-4,192 Reduced 7.32%	53,094 $24.9 Million
Q1 2024 May 06, 2024	SELL	$407.69 - $446.08 $10.3 Million - $11.2 Million	-25,163 Reduced 30.52%	57,286 $23.9 Million
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $2.07 Million - $2.48 Million	-6,045 Reduced 6.83%	82,449 $33.5 Million
Q3 2023 Nov 08, 2023	BUY	$338.18 - $362.46 $1.54 Million - $1.65 Million	4,553 Added 5.42%	88,494 $30.8 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $7.21 Million - $8.07 Million	22,918 Added 37.56%	83,941 $29.5 Million
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $794,460 - $906,295	-2,805 Reduced 4.39%	61,023 $19.2 Million
Q4 2022 Feb 08, 2023	BUY	$285.76 - $321.48 $3.96 Million - $4.46 Million	13,869 Added 27.76%	63,828 $18.4 Million
Q3 2022 Nov 09, 2022	SELL	$273.83 - $305.53 $2.15 Million - $2.4 Million	-7,848 Reduced 13.58%	49,959 $14.5 Million
Q2 2022 Aug 10, 2022	SELL	$234.96 - $292.55 $8.58 Million - $10.7 Million	-36,502 Reduced 38.7%	57,807 $16.3 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $6.52 Million - $7.68 Million	29,446 Added 45.4%	94,309 $24.6 Million
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $1.98 Million - $2.5 Million	11,205 Added 20.88%	64,863 $14.2 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $7.31 Million - $8.18 Million	40,274 Added 300.91%	53,658 $9.69 Million
Q2 2021 Aug 06, 2021	SELL	$187.49 - $221.1 $422,039 - $497,696	-2,251 Reduced 14.4%	13,384 $2.69 Million
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $3.24 Million - $3.77 Million	15,635 New	15,635 $3.36 Million
Q4 2020 Feb 10, 2021	SELL	$207.01 - $276.09 $2.73 Million - $3.64 Million	-13,185 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $461,703 - $547,398	1,806 Added 15.87%	13,185 $3.59 Million
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $317,926 - $417,078	1,410 Added 14.14%	11,379 $3.31 Million
Q1 2020 May 21, 2020	SELL	$199.77 - $247.81 $38,555 - $47,827	-193 Reduced 1.9%	9,969 $2.38 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $250,398 - $336,312	1,502 Added 17.34%	10,162 $2.23 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $325,478 - $366,322	1,958 Added 29.22%	8,660 $1.47 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $192,593 - $222,732	1,170 Added 21.15%	6,702 $1.23 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $223,655 - $265,960	-1,366 Reduced 19.8%	5,532 $1.02 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $513,911 - $650,246	-3,383 Reduced 32.91%	6,898 $1.14 Million
Q3 2018 Nov 09, 2018	BUY	$167.73 - $192.74 $553,005 - $635,463	3,297 Added 47.21%	10,281 $1.99 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $39,927 - $46,569	274 Added 4.08%	6,984 $1.19 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $204,053 - $238,416	-1,346 Reduced 16.71%	6,710 $1.09 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $1.09 Million - $1.23 Million	-7,931 Reduced 49.61%	8,056 $1.2 Million
Q3 2017 Nov 14, 2017	SELL	$148.13 - $162.24 $442,612 - $484,773	-2,988 Reduced 15.75%	15,987 $2.43 Million
Q2 2017 Aug 14, 2017	BUY	N/A	18,975	18,975 $2.45 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Account

High Tower Advisors, LLC Vertex Pharmaceuticals Inc Transaction History